Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Adverum Biotechnologies, Inc (ADVM)  
$7.90 0.04 (0.51%) as of 4:30 Wed 5/22


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 101,000,000
Market Cap: 797.90(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.7528 - $16.06
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    : 9.5
Insider 3/6 Months : 10.1
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Co.'s primary product candidate, ADVM-022, is a single, in-office intravitreal (IVT) injection gene therapy product. ADVM-022 is being developed for the treatment of patients with wet age-related macular degeneration who are responsive to anti-vascular endothelial growth factor therapy. Co.'s second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy via a single IVT injection.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 230,000 330,000 350,000
Total Buy Value $0 $310,500 $455,990 $472,790
Total People Bought 0 2 3 4
Total Buy Transactions 0 2 3 4
Total Shares Sold 0 0 6,201 140,082
Total Sell Value $0 $0 $9,429 $134,803
Total People Sold 0 0 1 5
Total Sell Transactions 0 0 1 9
End Date 2024-02-22 2023-11-21 2023-05-23 2022-05-23

   
Records found: 266
  Page 8 of 11  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Wachter Paul Director   –       •      –    2015-06-01 4 AS $36.11 $43,191 I/I (1,192) 39,545     -
   Schwartz Steven Daniel Director   –       •      –    2015-06-01 4 AS $36.11 $625,043 D/D (17,250) 384,806     -
   Guerin John Patrick Et Al Director   –       •       •   2015-05-28 4 S $208.00 $208 I/I (1) 150,699     -
   Gasmi Mehdi VP, Pharmaceutical Development   •       –      –    2015-05-28 4 AS $38.02 $19,009 D/D (500) 7,000     -
   Gasmi Mehdi VP, Pharmaceutical Development   •       –      –    2015-05-28 4 OE $2.75 $1,375 D/D 500 7,500     -
   Guerin John Patrick Et Al Director   –       •       •   2015-05-27 4 S $206.00 $248,230 I/I (1,205) 150,700     -
   Wachter Paul Director   –       •      –    2015-05-26 4 AS $36.52 $44,037 I/I (1,192) 40,737     -
   Schwartz Steven Daniel Director   –       •      –    2015-05-22 4 AS $38.16 $647,687 D/D (16,875) 402,056     -
   Gasmi Mehdi VP, Pharmaceutical Development   •       –      –    2015-05-21 4 AS $38.87 $19,435 D/D (500) 7,000     -
   Gasmi Mehdi VP, Pharmaceutical Development   •       –      –    2015-05-21 4 OE $2.75 $1,375 D/D 500 7,500     -
   Blumenkranz Mark S. Director   –       •      –    2015-05-19 4 AS $36.91 $110,734 I/I (3,000) 10,531     -
   Wachter Paul Director   –       •      –    2015-05-18 4 AS $35.31 $42,086 I/I (1,192) 41,929     -
   Blumenkranz Mark S. Director   –       •      –    2015-05-15 4 AS $35.36 $798,553 D/D (22,500) 552,989     -
   Gasmi Mehdi VP, Pharmaceutical Development   •       –      –    2015-05-14 4 AS $35.31 $17,656 D/D (500) 7,000     -
   Gasmi Mehdi VP, Pharmaceutical Development   •       –      –    2015-05-14 4 OE $2.75 $1,375 D/D 500 7,500     -
   Blumenkranz Mark S. Director   –       •      –    2015-05-13 4 AS $34.94 $24,984 D/D (715) 575,489     -
   Bain Linda Chief Financial Officer   •       –      –    2015-05-13 4 AS $34.94 $9,959 D/D (285) 9,000     -
   Bain Linda Chief Financial Officer   •       –      –    2015-05-13 4 OE $3.15 $898 D/D 285 9,285     -
   Blumenkranz Mark S. Director   –       •      –    2015-05-11 4 AS $34.91 $62,323 D/D (1,785) 576,204     -
   Wachter Paul Director   –       •      –    2015-05-11 4 AS $32.80 $39,792 I/I (1,192) 43,121     -
   Bain Linda Chief Financial Officer   •       –      –    2015-05-11 4 AS $34.91 $24,964 D/D (715) 9,000     -
   Bain Linda Chief Financial Officer   •       –      –    2015-05-11 4 OE $3.15 $2,252 D/D 715 9,715     -
   Schwartz Steven Daniel Director   –       •      –    2015-05-08 4 AS $33.05 $570,092 D/D (17,250) 418,931     -
   Gasmi Mehdi VP, Pharmaceutical Development   •       –      –    2015-05-07 4 AS $33.28 $16,638 D/D (500) 7,000     -
   Gasmi Mehdi VP, Pharmaceutical Development   •       –      –    2015-05-07 4 OE $2.75 $1,375 D/D 500 7,500     -
  266 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 8 of 11
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us